Differential Methylation Profile of Ovarian Cancer in Tissues and Plasma

Overview

Journal J Mol Diagn

Publisher Elsevier

Specialties Molecular Biology
Pathology

Date 2008 Dec 17

PMID 19074590

Citations 39

Authors

Anatoliy Melnikov

Denise Scholtens

Andrew Godwin

Victor Levenson

Affiliations

Soon will be listed here.

Abstract

An accurate biomarker for detection of ovarian cancer may reduce cancer-related mortality. Using a previously developed microarray-based technique, we evaluated differences in DNA methylation profiles in a panel of 56 genes using sections of serous papillary adenocarcinomas and uninvolved ovaries (n=30) from women in a high-risk group. Methylation profiles were also generated for circulating DNA from blood of patients (n=33) and healthy controls (n=33). Using the most differentially methylated genes for naïve Bayesian analysis, we identified ten of these profiles as potentially informative in tissues. Various combinations of these genes produced 69% sensitivity and 70% specificity for cancer detection as estimated under a stratified, fivefold cross-validation protocol. In plasma, five genes were identified as informative; their combination had 85% sensitivity and 61% specificity for cancer detection. These results suggest that differential methylation profiling in heterogeneous samples has the potential to identify components of a composite biomarker that may detect ovarian cancer in blood with significant accuracy.

Citing Articles

BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine.

Panagopoulou M, Panou T, Gkountakos A, Tarapatzi G, Karaglani M, Tsamardinos I Clin Epigenetics. 2024; 16(1):178.

PMID: 39643918 PMC: 11622545. DOI: 10.1186/s13148-024-01787-8.

Transformer-based AI technology improves early ovarian cancer diagnosis using cfDNA methylation markers.

Li G, Zhang Y, Li K, Liu X, Lu Y, Zhang Z Cell Rep Med. 2024; 5(8):101666.

PMID: 39094578 PMC: 11384945. DOI: 10.1016/j.xcrm.2024.101666.

Ovarian Cancer Diagnosis and Prognosis Based on Cell-Free DNA Methylation.

Gao Y, Zhou N, Liu J Cancer Control. 2024; 31:10732748241255548.

PMID: 38764160 PMC: 11104031. DOI: 10.1177/10732748241255548.

High-Grade Serous Ovarian Cancer-A Risk Factor Puzzle and Screening Fugitive.

Wilczynski J, Paradowska E, Wilczynski M Biomedicines. 2024; 12(1).

PMID: 38275400 PMC: 10813374. DOI: 10.3390/biomedicines12010229.

Liquid biopsy in ovarian cancer in China and the world: current status and future perspectives.

Zhang H, Wang L, Wu H Front Oncol. 2024; 13:1276085.

PMID: 38169730 PMC: 10758434. DOI: 10.3389/fonc.2023.1276085.

References

Terasawa K, Sagae S, Toyota M, Tsukada K, Ogi K, Satoh A . Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res. 2004; 10(6):2000-6. DOI: 10.1158/1078-0432.ccr-0932-03. View

Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M . Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors. Anticancer Res. 2003; 22(6A):3191-6. View

Bryan E, Jokubaitis V, Chamberlain N, Baxter S, Dawson E, Choong D . Mutation analysis of EP300 in colon, breast and ovarian carcinomas. Int J Cancer. 2002; 102(2):137-41. DOI: 10.1002/ijc.10682. View

Menon U, Talaat A, Rosenthal A, Macdonald N, Jeyerajah A, Skates S . Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG. 2000; 107(2):165-9. DOI: 10.1111/j.1471-0528.2000.tb11685.x. View

Wilcox C, Baysal B, Gallion H, Strange M, DeLoia J . High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet. 2005; 159(2):114-22. DOI: 10.1016/j.cancergencyto.2004.12.017. View

Kamat A, Bischoff F, Dang D, Baldwin M, Han L, Lin Y . Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther. 2006; 5(10):1369-74. DOI: 10.4161/cbt.5.10.3240. View

Melnikov A, Scholtens D, Wiley E, Khan S, Levenson V . Array-based multiplex analysis of DNA methylation in breast cancer tissues. J Mol Diagn. 2008; 10(1):93-101. PMC: 2175548. DOI: 10.2353/jmoldx.2008.070077. View

Munkarah A, Chatterjee M, Tainsky M . Update on ovarian cancer screening. Curr Opin Obstet Gynecol. 2007; 19(1):22-6. DOI: 10.1097/GCO.0b013e328011ec99. View

Shridhar V, Bible K, Staub J, Avula R, Lee Y, Kalli K . Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res. 2001; 61(10):4258-65. View

10.

Gifford G, Paul J, Vasey P, Kaye S, Brown R . The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res. 2004; 10(13):4420-6. DOI: 10.1158/1078-0432.CCR-03-0732. View

11.

Gentleman R, Carey V, Bates D, Bolstad B, Dettling M, Dudoit S . Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5(10):R80. PMC: 545600. DOI: 10.1186/gb-2004-5-10-r80. View

12.

Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A . Cancer statistics, 2005. CA Cancer J Clin. 2005; 55(1):10-30. DOI: 10.3322/canjclin.55.1.10. View

13.

Geisler J, Hatterman-Zogg M, Rathe J, Buller R . Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst. 2002; 94(1):61-7. DOI: 10.1093/jnci/94.1.61. View

14.

Melnikov A, Gartenhaus R, Levenson A, Motchoulskaia N, Levenson Chernokhvostov V . MSRE-PCR for analysis of gene-specific DNA methylation. Nucleic Acids Res. 2005; 33(10):e93. PMC: 1145194. DOI: 10.1093/nar/gni092. View

15.

Olivier R, Lubsen-Brandsma M, Verhoef S, van Beurden M . CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol. 2005; 100(1):20-6. DOI: 10.1016/j.ygyno.2005.08.038. View

16.

Strathdee G, Appleton K, Illand M, Millan D, Sargent J, Paul J . Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol. 2001; 158(3):1121-7. PMC: 1850352. DOI: 10.1016/S0002-9440(10)64059-X. View

17.

Wiley A, Katsaros D, Chen H, de la Longrais I, Beeghly A, Puopolo M . Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer. 2006; 107(2):299-308. DOI: 10.1002/cncr.21992. View

18.

Bast Jr R . Status of tumor markers in ovarian cancer screening. J Clin Oncol. 2003; 21(10 Suppl):200s-205s. DOI: 10.1200/JCO.2003.01.068. View

19.

Jacobs I, Bast Jr R . The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989; 4(1):1-12. DOI: 10.1093/oxfordjournals.humrep.a136832. View

20.

Bast Jr R, Feeney M, Lazarus H, Nadler L, Colvin R, Knapp R . Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981; 68(5):1331-7. PMC: 370929. DOI: 10.1172/jci110380. View